Tumor growth inhibition through targeting liposomally bound curcumin to tumor vasculature

Journal of Controlled Release

Volumn 172, Issue 3, 2013, Pages 832-840

  Mondal, Goutam ^a,b   Barui, Sugata ^a   Saha, Soumen ^c   Chaudhuri, Arabinda ^c  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b Indian Institut of Chemical Biology   (India)

^c ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Curcumin formulations; Liposomal drug delivery; RGDK lipopeptides; Tumor growth inhibition; Tumor vasculature targeting

Indexed keywords

ANTI-TUMOR EFFICACY; CURCUMIN; DRUG DELIVERY SYSTEM; IMMUNOHISTOCHEMICAL STAINING; LIPOSOMAL FORMULATION; RGDK-LIPOPEPTIDES; TUMOR GROWTH; TUMOR VASCULATURE TARGETING;

BIOCHEMISTRY; CELL DEATH; DRUG DELIVERY; ENDOTHELIAL CELLS;

TUMORS;

ARGINYLGLYCYLASPARTYLYSINE; CHOLESTEROL; CURCUMIN; DIOLEOYLPHOSPHATIDYLCHOLINE; LIPOCORTIN 5; LIPOPEPTIDE; LIPOSOME; LYSINE DERIVATIVE; PROPIDIUM IODIDE; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MEDIATOR; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TISSUE SECTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

CURCUMIN FORMULATIONS; LIPOSOMAL DRUG DELIVERY; RGDK-LIPOPEPTIDES; TUMOR GROWTH INHIBITION; TUMOR VASCULATURE TARGETING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CURCUMIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIPOSOMES; MICE; MICE, INBRED C57BL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES;

EID: 84887199587     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.08.302     Document Type: Article

References (49)

1. X. Fan, C. Zhang, D.B. Liu, J. Yan, and H.P. Liang The clinical applications of curcumin: current state and the future Curr. Pharm. Des. 19 2013 2011 2031
2. A. Noorafshan, and S. Ashkani-Esfahani A review of therapeutic effects of curcumin Curr. Pharm. Des. 19 2013 2032 2046
3. S. Shishodia, H.M. Amin, R. Lai, and B.B. Aggarwal Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma Biochem. Pharmacol. 70 2005 700 713 (Pubitemid 41058705)
4. A. Mukhopadhyay Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation Oncogene 21 2002 8852 8861 (Pubitemid 36132405)
5. M. Singh, and N. Singh Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells Mol. Cell. Biochem. 325 2009 107 119
6. S. Aggarwal, H. Ichikawa, Y. Takada, S.K. Sandur, S. Shishodia, and B.B. Aggarwal Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation Mol. Pharmacol. 69 2006 195 206 (Pubitemid 43048906)
7. Z.Y. He, C.B. Shi, H. Wen, F.L. Li, B.L. Wang, and J. Wang Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin Cancer Invest. 29 2011 208 213
8. H.S. Liu, C.S. Ke, H.C. Cheng, C.Y. Huang, and C.L. Su Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A Mol. Pharmacol. 80 2011 638 646
9. M. Singh, and N. Singh Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells Mol. Cell. Biochem. 347 2011 1 11
10. S.H. Wu Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade- and mitochondria-dependent pathways Anticancer. Res. 30 2010 2125 2133
11. S. Bisht Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer Mol. Cancer Ther. 9 2010 2255 2264
12. R.E. Carroll Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia Cancer Prev. Res. (Phila.) 4 2011 354 364
13. R.A. Sharma Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance Clin. Cancer Res. 10 2004 6847 6854 (Pubitemid 39383033)
14. C. Braumann, N. Guenther, L.M. Loeffler, and W. Dubiel Liver metastases after colonic carcinoma-palliative chemotherapy plus curcumin Int. J. Colorectal Dis. 24 2009 859 860
15. R. Epelbaum, B. Vizel, and G. Bar-Sela Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer J. Clin. Oncol. 26 2008 15619
16. M. Kanai A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer Cancer Chemother. Pharmacol. 68 2011 157 164
17. N. Dhillon Phase II trial of curcumin in patients with advanced pancreatic cancer Clin. Cancer Res. 14 2008 4491 4499
18. M. Bayet-Robert Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer Cancer Biol. Ther. 9 2010 8 14
19. P. Anand, A.B. Kunnumakkara, R.A. Newman, and B.B. Aggarwal Bioavailability of curcumin: problems and promises Mol. Pharm. 4 2007 807 818
20. R.A. Sharma, W.P. Steward, and A.J. Gescher Pharmacokinetics and pharmacodynamics of curcumin Adv. Exp. Med. Biol. 595 2007 453 470
21. A. Vyas, P. Dandawate, S. Padhye, A. Ahmad, and F. Sarkar Perspectives on new synthetic curcumin analogs and their potential anticancer properties Curr. Pharm. Des. 19 2013 2047 2069
22. L. Lan, B.S. Fadi, and K. Razelle Liposome-encapsulated curcumin in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis Cancer 104 2005 1322 1331
23. H.S. Shi A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiation Int. J. Nanomedicine 7 2012 2601 2611
24. S. Rahman Native and β-cyclodextrin-enclosed curcumin: entrapment within liposomes and their in vitro cytotoxicity in lung and colon cancer Drug Deliv. 19 2012 346 353
25. W.S. Orr Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition Surgery 151 2012 736 744
26. P.R. Dandawate Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer Pharm. Res. 29 2012 1775 1786
27. P. Kundu, C. Mohanty, and S.K. Sahoo Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy Acta Biomater. 8 2012 2670 2687
28. S. Komal Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention Cancer Res. 70 2010 4443 4452
29. C. Gong Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles Biomaterials 34 2013 1413 1432
30. S.M. Weis, and D.A. Cheresh Tumor angiogenesis: molecular pathways and therapeutic targets Nat. Med. 17 2011 1359 1370
31. J.S. Desgrosellier, and D.A. Cheresh Integrins in cancer: biological implications and therapeutic opportunities Nat. Rev. Cancer 10 2010 9 22
32. E. Ruoslahti Peptides as targeting elements and tissue penetration devices for nanoparticles Adv. Mater. 24 2012 3747 3756
33. K. Chen, and X. Chen Integrin targeted delivery of chemotherapeutics Theranostics 1 2011 189 200
34. D. Pramanik Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic α5β1 integrin receptor and mouse tumor vasculature J. Med. Chem. 51 2008 7298 7302
35. S. Samanta, R. Sistla, and A. Chaudhuri The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth Biomaterials 31 2010 1787 1797
36. R.L. Thangapazham Evaluation of a nanotechnology based carrier for delivery of curcumin in prostate cancer cells Int. J. Oncol. 32 2008 1119 1123
37. A.L. Cheng Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions Anticancer. Res. 21 2001 2895 2900
38. G. Garcea Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration Br. J. Cancer 90 2004 1011 1015 (Pubitemid 38499692)
39. M. Lopez-Lazaro Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent Mol. Nutr. Food Res. 52 Suppl. 1 2008 S103 S127
40. R.C. Cherny, M.A. Honan, and P. Thiagarajan Site-directed mutagenesis of the arginine-glycine-aspartic acid in vitronectin abolishes cell adhesion J. Biol. Chem. 268 1993 9725 9729 (Pubitemid 23146033)
41. A. Magnussen Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels Cancer Res. 65 2005 2712 2721 (Pubitemid 40490072)
42. G. Mondal, S. Barui, and A. Chaudhuri The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor Biomaterials 34 2013 6249 6260
43. M.K. Bharat Enhanced intravenous transgene expression in mouse lung using cyclic-head cationic lipids Chem. Biol. 11 2004 427 437
44. H.L. Pahl Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 18 1999 6853 6866
45. F. Thayyullathil Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells Free Radic. Biol. Med. 45 2008 1403 1412
46. A.B. Kunnumakkara Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model Int. J. Cancer 125 2009 2187 2197
47. B. Bachmeier, A.G. Nerlich, and C.M. Iancu The chemopreventive polyphenol curcumin prevents hematogenous breast cancer metastases in immunodeficient mice Cell. Physiol. Biochem. 19 2007 137 152
48. B.B. Aggarwal Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice Clin. Cancer Res. 11 2005 7490 7498 (Pubitemid 41507710)
49. S.H. Chen Activated STAT3 is a mediator and biomarker of VEGF endothelial activation Cancer Biol. Ther. 7 2008 1994-03